Thus, IL12-MSA was able to reduce the Treg frequency in tumor-bearing lungs even in the presence of IL2-MSA, despite concomitant expansion of Tregs in secondary lymphoid tissues during combination treatment. Here, IL2 is linked to neoplasm.